Marek Kania

571 total citations
26 papers, 196 citations indexed

About

Marek Kania is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Marek Kania has authored 26 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Marek Kania's work include Colorectal Cancer Treatments and Studies (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Marek Kania is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Marek Kania collaborates with scholars based in United States, Italy and Spain. Marek Kania's co-authors include Jalid Sehouli, Annamaria H. Zimmermann, Christopher Kaiser, Ignace Vergote, Hilary Calvert, Arvind Dasari, Jan Lehmann, Heikki Joensuu, Hans von der Maase and Gwénaëlle Gravis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Marek Kania

23 papers receiving 192 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marek Kania United States	8	119	66	56	52	35	26	196
Jennifer McLachlan United Kingdom	10	113 0.9×	45 0.7×	58 1.0×	74 1.4×	116 3.3×	21	280
Michael Korn United States	10	166 1.4×	62 0.9×	52 0.9×	57 1.1×	19 0.5×	18	256
И. А. Покатаев Russia	7	141 1.2×	101 1.5×	78 1.4×	35 0.7×	23 0.7×	86	246
Venu Bathini United States	8	102 0.9×	40 0.6×	57 1.0×	36 0.7×	9 0.3×	23	171
М. Yu. Fedyanin Russia	8	198 1.7×	104 1.6×	83 1.5×	41 0.8×	12 0.3×	107	308
Ken Kato Japan	12	187 1.6×	160 2.4×	133 2.4×	52 1.0×	21 0.6×	42	341
Patrizia Froesch Switzerland	12	226 1.9×	242 3.7×	30 0.5×	66 1.3×	14 0.4×	31	360
Vasiliki Michalarea United Kingdom	7	104 0.9×	54 0.8×	31 0.6×	34 0.7×	6 0.2×	17	162
G.M. Mead United Kingdom	7	51 0.4×	67 1.0×	44 0.8×	26 0.5×	12 0.3×	12	186

Countries citing papers authored by Marek Kania

Since Specialization

Citations

This map shows the geographic impact of Marek Kania's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Kania with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Kania more than expected).

Fields of papers citing papers by Marek Kania

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Kania. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Kania. The network helps show where Marek Kania may publish in the future.

Co-authorship network of co-authors of Marek Kania

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Kania. A scholar is included among the top collaborators of Marek Kania based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Kania. Marek Kania is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotani, Daisuke, Takayuki Yoshino, Toshiki Masuishi, et al.. (2025). Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. International Journal of Clinical Oncology. 30(10). 2043–2052.

Wang‐Gillam, Andrea, et al.. (2023). Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Investigational New Drugs. 41(6). 851–860. 7 indexed citations

Sobrero, Alberto, Sara Lonardi, Rocio García‐Carbonero, et al.. (2023). Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.. Journal of Clinical Oncology. 41(4_suppl). 67–67. 5 indexed citations

Dasari, Arvind, Joleen M. Hubbard, Cathy Eng, et al.. (2022). Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.. Journal of Clinical Oncology. 40(4_suppl). 93–93.

Movva, Sujana, Alexander I. Spira, Erika Hamilton, et al.. (2022). Surufatinib in U.S. patients with soft tissue sarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11557–11557. 1 indexed citations

Dasari, Arvind, Alberto Sobrero, James C. Yao, et al.. (2021). FRESCO-2: A Global Phase III Study Investigating the Efficacy and Safety of Fruquintinib in Metastatic Colorectal Cancer. Future Oncology. 17(24). 3151–3162. 31 indexed citations

Jankú, Filip, et al.. (2021). A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.. Journal of Clinical Oncology. 39(15_suppl). TPS3159–TPS3159. 1 indexed citations

Hubbard, Joleen M., Antonio Fernández, Santosh Kumar Nanda, et al.. (2020). 458P Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic colorectal cancer (mCRC). Annals of Oncology. 31. S436–S437. 1 indexed citations

Hahka‐Kemppinen, Marjo, et al.. (2020). A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma. Blood. 136(Supplement 1). 17–18. 3 indexed citations

10.

Dasari, Arvind, Daneng Li, Max W. Sung, et al.. (2020). Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).. Journal of Clinical Oncology. 38(15_suppl). 4610–4610. 15 indexed citations

11.

Hahka‐Kemppinen, Marjo, et al.. (2020). Abstract 5234: A phase I study of HMPL-689, a small molecule selective inhibitor of phosphoinositide 3-kinase-delta, inpatients with relapsed or refractory lymphoma. Cancer Research. 80(16_Supplement). 5234–5234. 2 indexed citations

12.

Cohen, Jonathon B., et al.. (2019). A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma. Annals of Oncology. 30. v448–v448.

13.

Hamilton, Erika, Allen Lee Cohn, Nicholas Sauter, et al.. (2019). Safety and tolerability of surufatinib in western patients with solid tumours. Annals of Oncology. 30. v569–v570. 1 indexed citations

14.

Dreicer, Robert, Jorge García, Brian Rini, et al.. (2013). A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Investigational New Drugs. 31(4). 1044–1050. 13 indexed citations

15.

Schmidinger, Manuela, Cezary Szczylik, Cora N. Sternberg, et al.. (2011). Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology. 35(5). 493–497. 7 indexed citations

16.

Dreicer, Robert, Jorge García, Maha Hussain, et al.. (2010). Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Investigational New Drugs. 29(6). 1441–1448. 10 indexed citations

17.

Vergote, Ignace, Hilary Calvert, Marek Kania, et al.. (2009). A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. European Journal of Cancer. 45(8). 1415–1423. 40 indexed citations

18.

Vergote, Ignace, Frédéric Amant, Luna Musib, et al.. (2009). Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer Results From a Safety Lead-in Study. International Journal of Gynecological Cancer. 19(9). 1505–1510. 7 indexed citations

19.

Sehouli, Jalid, et al.. (2008). A phase I/II study of pemetrexed in combination with carboplatin in patients with platin sensitive recurrent ovarian or peritoneal cancer (PSOC). Journal of Clinical Oncology. 26(15_suppl). 16513–16513. 1 indexed citations

20.

Maase, Hans von der, Jan Lehmann, Gwénaëlle Gravis, et al.. (2006). A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Annals of Oncology. 17(10). 1533–1538. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact